小剂量西地兰在婴幼儿重症肺炎心力衰竭前期 给药的临床价值分析.docVIP

小剂量西地兰在婴幼儿重症肺炎心力衰竭前期 给药的临床价值分析 　　摘要：目的:探究在婴幼儿重症肺炎心力衰竭前期行小剂量西地兰治疗的临床价值，并进行分析。方法:对我院2011年12月~2013年12月住院部收治的86例重症肺炎患儿展开研究，将其按照不同的治疗方式分为研究组和对照组，对照组行常规治疗，研究组在对照组的基础上加用小剂量西地兰治疗，对比分析两组患儿的临床疗效。结果:研究组患儿心衰发生率为9.30%较对照组的39.53%低，两组患儿在心衰率、治疗总有效率的比较上χ2=10.5238、4.4444，p0.05；在心率、呼吸恢复时间及住院时间的比较上t=5.8442、2.4992，p0.05；差异具有统计学意义。结论:在婴幼儿重症肺炎心力衰竭前期行小剂量西地兰治疗有效降低了心衰的发生率，缩短病程，安全有效，具有很高的临床使用价值。 　　关键词：婴幼儿重症肺炎；西地兰；心力衰竭；临床价值 　　Abstract：Objective: To explore the clinical value of heart failure in infants with severe pneumonia earlier lines of small dose cedilanid therapy, and carries on the analysis. Method: 86 cases of children with severe pneumonia inpatients admitted in our hospital from 2011 December to ~2013 in December, according to the different treatment methods are divided into the study group and the control group, the control group received routine therapy, study group in the control group based on the use of small dose cedilanid therapy, compared two groups of clinical curative effects children. Results: the study group with heart failure rate was 9.30% compared with 39.53% in the control group, two groups were compared in the heart failure rate, the total efficiency of treatment on X 2 =10.5238, 4.4444, P 0.05; the recovery time in the heart rate, breathing and hospitalization time on t=5.8442, 2.4992, P 0.05; with statistical significance differences. Conclusion: heart failure in infants with severe pneumonia earlier lines of small dose cedilanid therapy can effectively reduce the incidence of heart failure, shorten the course of disease, safe and effective, with a high clinical value. 　　keyword： severe infant pneumonia; cedilanid; heart failure; clinical value 　　婴幼儿重症肺炎是临床儿科常见的危重疾病，常合并严重的并发症，如心力衰竭，以右心衰竭为主，是导致患儿死亡的首要原因。如果能够在心衰早期确诊并采取积极有效的治疗，便可降低死亡率[1]。为此我院展开了对86例重症肺炎患儿的不同治疗方法的探究，旨在了解小剂量西地兰在心衰前期给药对患儿产生的疗效，现进行如下跟踪报道。 　　1资料与方法 　　1.1一般资料 　　选取2011年06（12）月~2013年06（12）月我院住院部收治的86例重症肺炎患儿为研究对象，将其按照治疗方式的不同分为研究组和对照组，每组43例患儿，其中研究组男婴28例，女婴15例；年龄1个月~3岁，平均（1.8±0.5）岁；病程在5~10d，平均（7.8±